» Articles » PMID: 34778056

Deep Learning-Based Computer-Aided Detection System for Automated Treatment Response Assessment of Brain Metastases on 3D MRI

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Nov 15
PMID 34778056
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although accurate treatment response assessment for brain metastases (BMs) is crucial, it is highly labor intensive. This retrospective study aimed to develop a computer-aided detection (CAD) system for automated BM detection and treatment response evaluation using deep learning.

Methods: We included 214 consecutive MRI examinations of 147 patients with BM obtained between January 2015 and August 2016. These were divided into the training (174 MR images from 127 patients) and test datasets according to temporal separation (temporal test set #1; 40 MR images from 20 patients). For external validation, 24 patients with BM and 11 patients without BM from other institutions were included (geographic test set). In addition, we included 12 MRIs from BM patients obtained between August 2017 and March 2020 (temporal test set #2). Detection sensitivity, dice similarity coefficient (DSC) for segmentation, and agreements in one-dimensional and volumetric Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria between CAD and radiologists were assessed.

Results: In the temporal test set #1, the sensitivity was 75.1% (95% confidence interval [CI]: 69.6%, 79.9%), mean DSC was 0.69 ± 0.22, and false-positive (FP) rate per scan was 0.8 for BM ≥ 5 mm. Agreements in the RANO-BM criteria were moderate (, 0.52) and substantial (, 0.68) for one-dimensional and volumetric, respectively. In the geographic test set, sensitivity was 87.7% (95% CI: 77.2%, 94.5%), mean DSC was 0.68 ± 0.20, and FP rate per scan was 1.9 for BM ≥ 5 mm. In the temporal test set #2, sensitivity was 94.7% (95% CI: 74.0%, 99.9%), mean DSC was 0.82 ± 0.20, and FP per scan was 0.5 (6/12) for BM ≥ 5 mm.

Conclusions: Our CAD showed potential for automated treatment response assessment of BM ≥ 5 mm.

Citing Articles

The value of AI for assessing longitudinal brain metastases treatment response.

Andrearczyk V, Schiappacasse L, Raccaud M, Bourhis J, Prior J, Cuendet M Neurooncol Adv. 2025; 7(1):vdae216.

PMID: 39896076 PMC: 11786217. DOI: 10.1093/noajnl/vdae216.


A federated learning architecture for secure and private neuroimaging analysis.

Stripelis D, Gupta U, Saleem H, Dhinagar N, Ghai T, Anastasiou C Patterns (N Y). 2024; 5(8):101031.

PMID: 39233693 PMC: 11368680. DOI: 10.1016/j.patter.2024.101031.


Automated segmentation of brain metastases with deep learning: A multi-center, randomized crossover, multi-reader evaluation study.

Luo X, Yang Y, Yin S, Li H, Shao Y, Zheng D Neuro Oncol. 2024; 26(11):2140-2151.

PMID: 38991556 PMC: 11639187. DOI: 10.1093/neuonc/noae113.


Prediction of treatment response after stereotactic radiosurgery of brain metastasis using deep learning and radiomics on longitudinal MRI data.

Cho S, Cho W, Choi D, Sim G, Jeong S, Baik S Sci Rep. 2024; 14(1):11085.

PMID: 38750084 PMC: 11096355. DOI: 10.1038/s41598-024-60781-5.


Development of RLK-Unet: a clinically favorable deep learning algorithm for brain metastasis detection and treatment response assessment.

Son S, Joo B, Park M, Suh S, Oh H, Kim J Front Oncol. 2024; 13:1273013.

PMID: 38288101 PMC: 10823345. DOI: 10.3389/fonc.2023.1273013.


References
1.
Ambrosini R, Wang P, ODell W . Computer-aided detection of metastatic brain tumors using automated three-dimensional template matching. J Magn Reson Imaging. 2009; 31(1):85-93. PMC: 2799295. DOI: 10.1002/jmri.22009. View

2.
Zhou Z, Sanders J, Johnson J, Gule-Monroe M, Chen M, Briere T . Computer-aided Detection of Brain Metastases in T1-weighted MRI for Stereotactic Radiosurgery Using Deep Learning Single-Shot Detectors. Radiology. 2020; 295(2):407-415. PMC: 8287889. DOI: 10.1148/radiol.2020191479. View

3.
Cho S, Sunwoo L, Baik S, Bae Y, Choi B, Kim J . Brain metastasis detection using machine learning: a systematic review and meta-analysis. Neuro Oncol. 2020; 23(2):214-225. PMC: 7906058. DOI: 10.1093/neuonc/noaa232. View

4.
Wen P, Chang S, van den Bent M, Vogelbaum M, Macdonald D, Lee E . Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol. 2017; 35(21):2439-2449. PMC: 5516482. DOI: 10.1200/JCO.2017.72.7511. View

5.
Kaufmann T, Smits M, Boxerman J, Huang R, Barboriak D, Weller M . Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro Oncol. 2020; 22(6):757-772. PMC: 7283031. DOI: 10.1093/neuonc/noaa030. View